Impact of Multidrug Resistance on the Virulence and Fitness of Pseudomonas Aeruginosa: a Microbiological and Clinical Perspective

Overview

Journal Infection

Date 2024 Jul 2

PMID 38954392

Authors

Elena Sendra

Almudena Fernandez-Munoz

Laura Zamorano

Antonio Oliver

Juan Pablo Horcajada

Carlos Juan

Silvia Gomez-Zorrilla

Affiliations

Soon will be listed here.

Abstract

Pseudomonas aeruginosa is one of the most common nosocomial pathogens and part of the top emergent species associated with antimicrobial resistance that has become one of the greatest threat to public health in the twenty-first century. This bacterium is provided with a wide set of virulence factors that contribute to pathogenesis in acute and chronic infections. This review aims to summarize the impact of multidrug resistance on the virulence and fitness of P. aeruginosa. Although it is generally assumed that acquisition of resistant determinants is associated with a fitness cost, several studies support that resistance mutations may not be associated with a decrease in virulence and/or that certain compensatory mutations may allow multidrug resistance strains to recover their initial fitness. We discuss the interplay between resistance profiles and virulence from a microbiological perspective but also the clinical consequences in outcomes and the economic impact.

Citing Articles

Microbial dysbiosis in periodontitis and peri-implantitis: pathogenesis, immune responses, and therapeutic.

Cui Z, Wang P, Gao W Front Cell Infect Microbiol. 2025; 15:1517154.

PMID: 40007610 PMC: 11850578. DOI: 10.3389/fcimb.2025.1517154.

Association of Causative Pathogens With Acute Kidney Injury in Adult Patients With Community-Onset Sepsis.

Pant P, Chihara S, Krishnamoorthy V, Treggiari M, Messina J, Privratsky J Crit Care Explor. 2025; 7(2):e1219.

PMID: 39937578 PMC: 11826047. DOI: 10.1097/CCE.0000000000001219.

-Alkane Assimilation by and Its Interactions with Virulence and Antibiotic Resistance.

Libisch B Antibiotics (Basel). 2024; 13(11).

PMID: 39596723 PMC: 11591199. DOI: 10.3390/antibiotics13111028.

Emergence of NDM-1-Producing Nosocomial Isolates in Attica Region of Greece.

Pappa O, Louka C, Karadimas K, Maikousi E, Tzoukmani A, Polemis M Microorganisms. 2024; 12(9).

PMID: 39338428 PMC: 11434298. DOI: 10.3390/microorganisms12091753.

Deciphering the molecular mechanisms underlying anti-pathogenic potential of a polyherbal formulation Enteropan® against multidrug-resistant .

Parmar S, Gajera G, Thakkar N, Palep H, Kothari V Drug Target Insights. 2024; 18:54-69.

PMID: 39224464 PMC: 11367655. DOI: 10.33393/dti.2024.3082.

References

Rodriguez-Rojas A, Macia M, Couce A, Gomez C, Castaneda-Garcia A, Oliver A . Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One. 2010; 5(4):e10193. PMC: 2855370. DOI: 10.1371/journal.pone.0010193. View

El-Solh A, Hattemer A, Hauser A, Alhajhusain A, Vora H . Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2011; 40(4):1157-63. PMC: 3288436. DOI: 10.1097/CCM.0b013e3182377906. View

Bou R, Lorente L, Aguilar A, Perpinan J, Ramos P, Peris M . Hospital economic impact of an outbreak of Pseudomonas aeruginosa infections. J Hosp Infect. 2008; 71(2):138-42. DOI: 10.1016/j.jhin.2008.07.018. View

Pirzadian J, Persoon M, Severin J, Klaassen C, De Greeff S, Mennen M . National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017. Sci Rep. 2021; 11(1):21015. PMC: 8545960. DOI: 10.1038/s41598-021-00205-w. View

Chen L, Zou Y, Kronfl A, Wu Y . Type VI secretion system of Pseudomonas aeruginosa is associated with biofilm formation but not environmental adaptation. Microbiologyopen. 2020; 9(3):e991. PMC: 7066461. DOI: 10.1002/mbo3.991. View

Yahav D, Giske C, Gramatniece A, Abodakpi H, Tam V, Leibovici L . New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020; 34(1). PMC: 7667665. DOI: 10.1128/CMR.00115-20. View

Barcelo I, Jordana-Lluch E, Escobar-Salom M, Torrens G, Fraile-Ribot P, Cabot G . Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa. Microbiol Spectr. 2022; 10(5):e0270022. PMC: 9604156. DOI: 10.1128/spectrum.02700-22. View

Escobar-Salom M, Barcelo I, Jordana-Lluch E, Torrens G, Oliver A, Juan C . Bacterial virulence regulation through soluble peptidoglycan fragments sensing and response: knowledge gaps and therapeutic potential. FEMS Microbiol Rev. 2023; 47(2). PMC: 10039701. DOI: 10.1093/femsre/fuad010. View

Balasubramanian D, Schneper L, Merighi M, Smith R, Narasimhan G, Lory S . The regulatory repertoire of Pseudomonas aeruginosa AmpC ß-lactamase regulator AmpR includes virulence genes. PLoS One. 2012; 7(3):e34067. PMC: 3315558. DOI: 10.1371/journal.pone.0034067. View

10.

Gellatly S, Hancock R . Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013; 67(3):159-73. DOI: 10.1111/2049-632X.12033. View

11.

Cosgrove S . The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2005; 42 Suppl 2:S82-9. DOI: 10.1086/499406. View

12.

Ma L, Wang D, Liu Y, Zhang Z, Wozniak D . Regulation of Biofilm Exopolysaccharide Biosynthesis and Degradation in . Annu Rev Microbiol. 2022; 76:413-433. DOI: 10.1146/annurev-micro-041320-111355. View

13.

Tabak Y, Merchant S, Ye G, Vankeepuram L, Gupta V, Kurtz S . Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States. J Hosp Infect. 2019; 103(2):134-141. DOI: 10.1016/j.jhin.2019.06.005. View

14.

Gallant C, Daniels C, Leung J, Ghosh A, Young K, Kotra L . Common beta-lactamases inhibit bacterial biofilm formation. Mol Microbiol. 2005; 58(4):1012-24. PMC: 3097517. DOI: 10.1111/j.1365-2958.2005.04892.x. View

15.

Sanchez-Diener I, Zamorano L, Lopez-Causape C, Cabot G, Mulet X, Pena C . Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model. Antimicrob Agents Chemother. 2017; 61(12). PMC: 5700365. DOI: 10.1128/AAC.01586-17. View

16.

Overhage J, Bains M, Brazas M, Hancock R . Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance. J Bacteriol. 2008; 190(8):2671-9. PMC: 2293252. DOI: 10.1128/JB.01659-07. View

17.

Burrows L . Pseudomonas aeruginosa twitching motility: type IV pili in action. Annu Rev Microbiol. 2012; 66:493-520. DOI: 10.1146/annurev-micro-092611-150055. View

18.

Colmer-Hamood J, Dzvova N, Kruczek C, Hamood A . In Vitro Analysis of Pseudomonas aeruginosa Virulence Using Conditions That Mimic the Environment at Specific Infection Sites. Prog Mol Biol Transl Sci. 2016; 142:151-91. DOI: 10.1016/bs.pmbts.2016.05.003. View

19.

Luong P, Shogan B, Zaborin A, Belogortseva N, Shrout J, Zaborina O . Emergence of the P2 phenotype in Pseudomonas aeruginosa PAO1 strains involves various mutations in mexT or mexF. J Bacteriol. 2013; 196(2):504-13. PMC: 3911258. DOI: 10.1128/JB.01050-13. View

20.

Beceiro A, Tomas M, Bou G . Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin Microbiol Rev. 2013; 26(2):185-230. PMC: 3623377. DOI: 10.1128/CMR.00059-12. View